Abstract:Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which are simple to engineer and can reliably achieve high levels of protein expression. However, plasmids typically require antibiotics for maintenance, and the administration of an antibiotic is often incompatible with in vivo experimentation or treatment. EcN natively contains plasmids pMUT1 and pMUT2, which have no known function but are stable within the bacteria. Here, we describe the development of the pMUT plasmids into a robust platform for engineering EcN for in vivo experimentation, alongside a CRISPR-Cas9 system to remove the native plasmids. We systematically engineered both pMUT plasmids to contain selection markers, fluorescent markers, temperature sensitive expression, and curli secretion systems to export a customizable functional material into the extracellular space. We then demonstrate that the engineered plasmids were maintained in bacteria as the engineered bacteria pass through the mouse GI tract without selection, and that the secretion system remains functional, exporting functionalized curli proteins into the gut. Our plasmid system presents a platform for the rapid development of therapeutic EcN bacteria.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acssynbio.0c00466?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssynbio.0c00466</a>.Table S1: DNA primers used in this work; Table S2: Sequence of UNS sequences; Table S3: gRNA sequences used in the pFREE and pCryptDel plasmids; Table S4: Variant TlpA* promoter sequences, and their properties; Figure S1: Detailed plasmid maps of pMUT1 and pMUT2; Figure S2: GFP and RFP characterization of engineered pMUT plasmids; Figure S3: Plasmid vectors to cure EcN cryptic plasmids; Figure S4: Curing native pMUT plasmids; Figure S5: In vivo synthetic plasmid loss; Supplementary methods for Figure S5; Figure S6: In vitro growth characterization of bacteria used in vivo (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_001.pdf">PDF</a>)Dataset S1: All data used in the figures (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_002.xlsx">XLSX</a>)Dataset S2: In vivo data (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Conquering homocystinuria with engineered probiotics

The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers

Empowering probiotics with high xanthine transport for effective hyperuricemia management

The Impact of Nutrition, Physical Activity, Beneficial Microbes, and Fecal Microbiota Transplant for Improving Health

Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis

Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice

Engineering a Cortisol Sensing Enteric Probiotic

Controlled colonization of the human gut with a genetically engineered microbial medicine

Plasmid Vectors for in Vivo Selection-Free Use with the Probiotic E. coli Nissle 1917

Bioengineered Probiotics for Clostridioides difficile Infection: An Overview of the Challenges and Potential for This New Treatment Approach

Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain

Next generation probiotics: Engineering live biotherapeutics

Engineering Escherichia coli for diagnosis and management of hyperuricemia

Bio-engineering a common probiotic to exploit colonic inflammation promotes reliable efficacy in translational models of colitis

Improving the growth and intestinal colonization of Escherichia coli Nissle 1917 by strengthening its oligopeptides importation ability

Probiotic hat trick

Hypoxic Tumor Radiosensitization Using Engineered Probiotics

Rational design of a genome-based insulated system in Escherichia coli facilitates heterologous uricase expression for hyperuricemia treatment

Bioengineering of Escherichia coli Nissle 1917 for Production and Excretion of Spermidine, a Key Metabolite in Human Health

Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases

Probiotic Characterization of Lactobacillus brevis MJM60390 and In Vivo Assessment of Its Antihyperuricemic Activity